These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 33373106)

  • 1. Safety risk management for low molecular weight process-related impurities in monoclonal antibody therapeutics: Categorization, risk assessment, testing strategy, and process development with leveraging clearance potential.
    Luo H; Li Y; Robbins D; Wang SC; Xi G; Cox M; Nicholson SM; Wei C; Pabst TM; Wang WK
    Biotechnol Prog; 2021 May; 37(3):e3119. PubMed ID: 33373106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk-based Strategy to Determine Testing Requirement for the Removal of Residual Process Reagents as Process-related Impurities in Bioprocesses.
    Qiu J; Li K; Miller K; Raghani A
    PDA J Pharm Sci Technol; 2015; 69(3):334-45. PubMed ID: 26048741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of adsorptive hybrid filters to enable two-step purification of biologics.
    Singh N; Arunkumar A; Peck M; Voloshin AM; Moreno AM; Tan Z; Hester J; Borys MC; Li ZJ
    MAbs; 2017; 9(2):350-363. PubMed ID: 27929735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Host cell protein impurities in chromatographic polishing steps for monoclonal antibody purification.
    Levy NE; Valente KN; Lee KH; Lenhoff AM
    Biotechnol Bioeng; 2016 Jun; 113(6):1260-72. PubMed ID: 26550778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Innovative next-generation monoclonal antibody purification using activated carbon: A challenge for flow-through and column-free processes.
    Ishihara T; Miyahara M; Yamada T; Yamamoto K
    J Chromatogr B Analyt Technol Biomed Life Sci; 2019 Jul; 1121():72-81. PubMed ID: 31128526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Demonstration of robust host cell protein clearance in biopharmaceutical downstream processes.
    Shukla AA; Jiang C; Ma J; Rubacha M; Flansburg L; Lee SS
    Biotechnol Prog; 2008; 24(3):615-22. PubMed ID: 18410156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficiency of ultrafiltration/diafiltration in removing organic and elemental process equipment related leachables from biological therapeutics.
    Sun B; Hadidi M; Santiago Nuñez J; Song B; Tumambac GE; Wong K; Kalinowski G; Hathcock JJ
    Biotechnol Prog; 2024; 40(1):e3400. PubMed ID: 37964726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Creating a Holistic Extractables and Leachables (E&L) Program for Biotechnology Products.
    Li K; Rogers G; Nashed-Samuel Y; Lee H; Mire-Sluis A; Cherney B; Forster R; Yeh P; Markovic I
    PDA J Pharm Sci Technol; 2015; 69(5):590-619. PubMed ID: 26429108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retrospective Evaluation of Cycled Resin in Viral Clearance Studies-A Multiple Company Collaboration.
    Mattila J; Curtis S; Webb-Vargas Y; Wilson E; Galperina O; Roush D; Tobler S; Stanley B; Clark M; Weaver J; Pike J; Yu D; Li X; Flicker A; Kindermann J; Schuelke N; Whitcombe R; Bennett L
    PDA J Pharm Sci Technol; 2019; 73(5):470-486. PubMed ID: 31101706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determining the Clearance of Degraded Protein via a Monoclonal Antibody Purification Process in Support of Cleaning Carryover Limits in Multiproduct Facilities.
    Che PL; Bailey AP; Tam CYJ; Alvarez M; Arroyo AY
    PDA J Pharm Sci Technol; 2020; 74(4):377-393. PubMed ID: 32179711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of product-related low molecular weight impurities in therapeutic monoclonal antibodies using hydrophilic interaction chromatography coupled with mass spectrometry.
    Wang S; Liu AP; Yan Y; Daly TJ; Li N
    J Pharm Biomed Anal; 2018 May; 154():468-475. PubMed ID: 29587227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploration of overloaded cation exchange chromatography for monoclonal antibody purification.
    Liu HF; McCooey B; Duarte T; Myers DE; Hudson T; Amanullah A; van Reis R; Kelley BD
    J Chromatogr A; 2011 Sep; 1218(39):6943-52. PubMed ID: 21871630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Achieving a Successful Scale-Down Model and Optimized Economics through Parvovirus Filter Validation using Purified TrueSpikeTM Viruses.
    De Vilmorin P; Slocum A; Jaber T; Schaefer O; Ruppach H; Genest P
    PDA J Pharm Sci Technol; 2015; 69(3):440-9. PubMed ID: 26048749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Limits in virus filtration capability? Impact of virus quality and spike level on virus removal with xenotropic murine leukemia virus.
    Roush DJ; Myrold A; Burnham MS; And JV; Hughes JV
    Biotechnol Prog; 2015; 31(1):135-44. PubMed ID: 25395156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Viral clearance using disposable systems in monoclonal antibody commercial downstream processing.
    Zhou JX; Solamo F; Hong T; Shearer M; Tressel T
    Biotechnol Bioeng; 2008 Jun; 100(3):488-96. PubMed ID: 18438883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimization of a platform process operating space for a monoclonal antibody susceptible to reversible and irreversible aggregation using a solution stability screening approach.
    Man A; Luo H; Levitskaya SV; Macapagal N; Newell KJ
    J Chromatogr A; 2019 Jul; 1597():100-108. PubMed ID: 30922716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Processing Impact on Monoclonal Antibody Drug Products: Protein Subvisible Particulate Formation Induced by Grinding Stress.
    Gikanga B; Eisner DR; Ovadia R; Day ES; Stauch OB; Maa YF
    PDA J Pharm Sci Technol; 2017; 71(3):172-188. PubMed ID: 27789805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Host cell proteins in biotechnology-derived products: A risk assessment framework.
    de Zafra CL; Quarmby V; Francissen K; Vanderlaan M; Zhu-Shimoni J
    Biotechnol Bioeng; 2015 Nov; 112(11):2284-91. PubMed ID: 26010760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mixing monoclonal antibody formulations using bottom-mounted mixers: impact of mechanism and design on drug product quality.
    Gikanga B; Chen Y; Stauch OB; Maa YF
    PDA J Pharm Sci Technol; 2015; 69(2):284-96. PubMed ID: 25868994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ELISA reagent coverage evaluation by affinity purification tandem mass spectrometry.
    Henry SM; Sutlief E; Salas-Solano O; Valliere-Douglass J
    MAbs; 2017 Oct; 9(7):1065-1075. PubMed ID: 28708446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.